Bristol Myers Squibb announced positive results from the Phase 3 POETYK PsA-2 trial, showing that Sotyktu (deucravacitinib) significantly improved symptoms in adults with psoriatic arthritis (PsA) compared to placebo. At week 16, 54.2% of Sotyktu-treated patients achieved an ACR20 response, indicating at least a 20% improvement in disease symptoms, versus 39.4% on placebo. The treatment also led to greater improvements in skin symptoms (PASI 75) and quality of life.

Sotyktu was well tolerated, with a safety profile consistent with previous studies. The trial included an apremilast reference arm for safety comparison, with no new safety concerns identified. Adverse events occurred in 62.8% of Sotyktu patients compared to 54.7% on placebo and 73.3% on apremilast.

Sotyktu, an oral TYK2 inhibitor, is already approved for moderate-to-severe plaque psoriasis and is being evaluated for broader applications in immune-mediated diseases. Bristol Myers Squibb plans to present further POETYK PsA trial data at upcoming medical conferences and discuss results with regulatory authorities.